8 thoughts on “D15 – Wohlgenant

    1. Thanks for your question! In this experiment, we were treating ginkgetin as a chemotherapy (in combination with radiation. But future trials could certainly test whether ginkgetin could act synergistically with another known chemotherapy.

  1. Loved your presentation! Understanding that there are limitation you faced with limited amount of GK available, what led you to the conclusion that that GK can be effective?

    1. Great question! Previous research performed in human cancer cell lines was effective at preventing certain hallmarks of cancer such as resistance to apoptosis (cellular death) and reducing cell proliferation. Moreover, GK is a known inhibitor of a cancer-causing pathway, the JAK-STAT pathway.

  2. This poster was really great to listen to! I was wondering, how was this compound discovered? And, do you know if this compound is an inhibitor or causes damages to any other pathways or functions of the cell?

    1. Thanks for your question! The Ginkgo biloba plant is native to China and has been referenced as early as 2800 BC for use in treatment of various cardiovascular and neurological disorders. In short, it has persisted as a treatment in Eastern medicinal practices for centuries. It is also known to have anti-inflammatory effects (by down-regulating inflammation-causing cytokines) which is another property that might be useful in cancer treatment. There are no known problematic health effects (that I discovered in my literature review).

  3. This is a really well done presentation. In your personal opinion, do you think its worth pursuing research into ginkgetin or would efforts be better spent looking into other potential agents since it wasn’t far enough below the negative control?

    1. Thank you so much for asking this. I definitely believe pursuing research into ginkgetin is worthwhile. There is a lot of research that could be done to better determine the efficacy of this compound in cancer treatment on a very quick timescale (1-2 weeks) and at low cost, such as combining it with an efflux pump inhibitor, testing the drug at higher concentrations, and testing it in flies with known cancer mutations. If those additional trials were unsuccessful, however, I’d advise searching for a new hit compound before testing in a more advanced cancer model or even in expensive cancer cell lines.

Leave a Reply